Dexcom Supports NASCAR Driver Ryan Reed’s American Diabetes Association Drive to Stop Diabetes℠ Initiative

Dexcom, Inc., (NASDAQ:DXCM), the leader in continuous glucose monitoring (CGM), announced today it is supporting NASCAR driver Ryan Reed and the American Diabetes Association’s Drive to Stop Diabetes℠ national diabetes awareness initiative. As part of the campaign, Dexcom will support Ryan Reed and the Association’s Drive to Stop Diabetes presented by Lilly Diabetes to build awareness about the importance of daily monitoring and tracking of glucose trends in the management of diabetes.

“At the age of 17 I received the life-changing news that I had type 1 diabetes and was told I would never race again,” said Ryan Reed, NASCAR driver. “I refused to give up my racing dream and have since learned to manage my disease through a balanced diet, exercise and understanding my blood glucose. My Dexcom G4® Platinum has been my safety belt in tracking my glucose levels on major race days and in everyday life and for that, I am happy to be working with them.”

“Seeing a young man take on a demanding sport such as auto racing, while having to meticulously and continuously manage his blood glucose is an inspiration to the nearly 26 million Americans living with diabetes,” said Terrance H. Gregg, CEO of Dexcom. “Daily management is an ongoing challenge and Ryan’s success shows that people can overcome that challenge and pursue their dreams in spite of diabetes.”

At upcoming NASCAR races fans will have the opportunity to watch how Reed manages his No. 16 American Diabetes Association Drive to Stop Diabetes presented by Lilly Diabetes Ford Mustang, racing at speeds over 200 MPH, while also monitoring the speed and rate of change of his blood glucose. Just as Reed manages tight curves and close finishes, he also manages his blood glucose throughout the race to ensure that it remains at safe and healthy levels. As part of his races throughout the country, Reed will also be sharing his personal story of life with diabetes and his use of Dexcom technology to help him monitor his disease while he pursues and lives his dream.

Continuous glucose monitoring is considered the most significant breakthrough in diabetes management in the past 40 years. CGM is important because it can help educate patients on how to best learn to manage their diabetes.

The Dexcom G4® PLATINUM tracks glucose levels continuously and uses wireless technology to enable users to view their glucose levels on demand. The system allows persons with diabetes to program personalized information such as glucose targets and alerts, and it has an alarm feature to alert the user if glucose levels rise or fall to dangerous levels. This is important as uncontrolled glucose can cause health complications and even death.2 The Dexcom G4® PLATINUM CGM is newly approved by the U.S. Food and Drug Administration for children ages two to 17 years; it has been previously approved for patients aged 18 years and older. It is also the only CGM approved for children ages two to six.

About Dexcom, Inc.

Dexcom, Inc., headquartered in San Diego, California, develops and markets continuous glucose monitoring systems for use by persons with diabetes, as well as blood glucose monitoring systems used by healthcare providers in hospital critical care settings. For more information on the Dexcom CGM, visit www.dexcom.com.

BRIEF SAFETY STATEMENT

The Dexcom G4® PLATINUM (Pediatric) Continuous Glucose Monitoring System is a glucose monitoring device indicated for detecting trends and tracking patterns in persons (ages 2 to 17 years) with diabetes. CONTRAINDICATIONS: Remove the System before MRI, CT scan, or diathermy treatment. Taking acetaminophen while wearing the sensor may falsely raise your sensor glucose readings. WARNING: Do not use the System for treatment decisions. The System does not replace a blood glucose meter. In a pediatric clinical study, larger differences were observed between this CGM device and actual blood glucose values compared to those differences observed in the adult clinical study. Use your blood glucose meter for treatment decisions. In a pediatric clinical study, a significant number of low glucose events were not detected by CGM. Do not rely solely on CGM alerts to detect low glucose. If a sensor breaks and no portion of it is visible above the skin, do not attempt to remove it. Seek professional medical help if you have infection or inflammation. Report broken sensors to Dexcom Technical Support. The System is not approved for use in pregnant women or persons on dialysis. Sensor placement is not approved for sites other than under the skin of the belly or upper buttocks. Contact Dexcom Toll Free at 877-339-2664 or www.dexcom.com for detailed indications for use and safety information.

To view multimedia assets, please visit: http://www.multimedianewscenter.com/dexcom/dexcom-media-portal.

References

1. Clarke SF and Foster JR. A history of blood glucose meters and their role in self-monitoring of diabetes mellitus. Br J Biomed Sci. 2012;(3)2:83-93.

2. American Diabetes Association (http://www.diabetes.org/diabetes-basics/diabetes-statistics/)

Contacts:

CONSUMER:
Green Room Public Relations
Alexandra Schnabel, 201-618-2735
Alex@greenroompr.com
or
INVESTOR:
Dexcom, Inc.
Steven Pacelli, 858-200-0200

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.